Quarterly ResultAug 5, 2026, 04:24 PM
Evolus Q2 Revenue $84.1M (+21%); Raises FY26 Outlook & EBITDA Positive
AI Summary
Evolus, Inc. reported strong financial results for the second quarter ended June 30, 2026, with global net revenue reaching $84.1 million, a 21% increase over the prior year. The company achieved positive Adjusted EBITDA of $4.7 million for the third consecutive quarter, a significant improvement from a $7.9 million loss in Q2 2025. Based on these results, Evolus raised its full-year 2026 net revenue guidance to between $330 million and $337 million and increased its adjusted gross profit margin guidance. Additionally, Evolus expanded its global injectable portfolio through an exclusive U.S. partnership for Profhilo® and extended the Estyme® franchise into Canada, Australia, and New Zealand.
Key Highlights
- Q2 2026 Global Net Revenue was $84.1 million, an increase of 21% year-over-year.
- Q2 2026 Adjusted EBITDA was $4.7 million, marking the third consecutive positive quarter.
- Full-year 2026 net revenue guidance raised to between $330 million and $337 million.
- Full-year 2026 adjusted gross profit margin guidance raised to 67.0% to 67.5%.
- Entered exclusive U.S. partnership for Profhilo®, with estimated peak annual revenue over $100M.
- Expanded Estyme® franchise to Canada, Australia, and New Zealand for commercialization by 2028.
- Reaffirmed 2028 long-term net revenue outlook of $450 million to $500 million.
- Cash and cash equivalents stood at $45.2 million as of June 30, 2026.
Price Impact
More from EOLS